Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14745664 | 1.00 | KCNH2 (0.38) | KCNH2HTTSMN1; SMN2 | |
| SCHEMBL14745662 | 1.00 | KCNH2 (0.38) | KCNH2HTTSMN1; SMN2 | |
| SCHEMBL14758922 | 0.88 | BPTF (0.39) | KCNH2 | |
| SCHEMBL14758918 | 0.88 | KCNH2 (0.39) | KCNH2HTTSMN1; SMN2 | |
| SCHEMBL16568499 | 0.88 | KCNH2 (0.39) | KCNH2HTTSMN1; SMN2 | |
| SCHEMBL16568500 | 0.88 | KCNH2 (0.39) | KCNH2HTTSMN1; SMN2 | |
| SCHEMBL14745795 | 0.88 | KCNH2 (0.39) | KCNH2HTTSMN1; SMN2 | |
| SCHEMBL14745189 | 0.87 | KCNH2 (0.41) | KCNH2HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16568086 | 0.87 | KCNH2 (0.38) | KCNH2HTTSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL16568087 | 0.87 | KCNH2 (0.38) | KCNH2HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650395-B2 | Antibacterial compounds and methods for use | PTC THERAPEUTICS, INC. (US) | 2017-05-16 | — | — | US | claimed |
| WO-2016039936-A2 | MONOCYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | claimed |
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2015-03-19 | — | — | US | claimed |
| EP-2750505-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | claimed |
| WO-2013033240-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | claimed |
| WO-2016039936-A2 | MONOCYCLIC SUBSTITUTED 2-PYRIDINONE ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-2750505-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC Therapeutics, Inc. (US) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013033240-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | PTC THERAPEUTICS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080362-A1 | ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE | MRPL21, SLC11A2, CLPP | KCNH2 3306/4885HTT 4310/4885SMN1; SMN2 4224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.